Experienced in Midline Lethal Granuloma

Dr. Mark Hutchins

Oncology
Nebraska Hematology-Oncology PC
4004 Pioneer Woods Dr, 
Lincoln, NE 
Experienced in Midline Lethal Granuloma
Nebraska Hematology-Oncology PC
4004 Pioneer Woods Dr, 
Lincoln, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Hutchins is an Oncologist in Lincoln, Nebraska. Dr. Hutchins is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Paget Disease of the Breast, Multiple Myeloma, Inflammatory Breast Cancer, Lung Cancer, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NE
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Nebraska Hematology-Oncology PC
4004 Pioneer Woods Dr, Lincoln, NE 68506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Veliparib, Carboplatin
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 3 Less Clinical Trials

1 Total Publications

Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
Journal: Anticancer research
Published: September 04, 2016
Similar Doctors
Experienced in Midline Lethal Granuloma
Dr. Samer Renno
Oncology
Experienced in Midline Lethal Granuloma
Dr. Samer Renno
Oncology

Hematology & Oncology Consultants PC

6901 N 72nd St Ste 2244, 
Omaha, NE 
 (51.1 miles away)
402-562-2261
Languages Spoken:
English
See accepted insurances

Samer Renno is an Oncologist in Omaha, Nebraska. Dr. Renno is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Lynch Syndrome, and Colorectal Cancer.

Experienced in Midline Lethal Granuloma
Dr. Joel Michalski
Oncology
Experienced in Midline Lethal Granuloma
Dr. Joel Michalski
Oncology

Office

17201 Wright St Ste 200, 
Omaha, NE 
 (38.9 miles away)
402-334-4773
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joel Michalski is an Oncologist in Omaha, Nebraska. Dr. Michalski is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Pleuropulmonary Blastoma, Thrombocytopenia, Agranulocytosis, and Chronic Familial Neutropenia.

Experienced in Midline Lethal Granuloma
Dr. Inaganti Shah
Oncology
Experienced in Midline Lethal Granuloma
Dr. Inaganti Shah
Oncology

Hematology & Oncology Consultants PC

6901 N 72nd St Ste 2244, 
Omaha, NE 
 (51.1 miles away)
402-562-2261
Languages Spoken:
English
See accepted insurances

Inaganti Shah is an Oncologist in Omaha, Nebraska. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Lynch Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hutchins's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile